Marktlink → Sectors → Materials & Energy → Chemicals

  • Updated February 27, 2026

Specialization commands the premium

The chemicals M&A market rewards specificity over scale. Specialty formulators with proprietary products and customer lock-in consistently outperform commodity producers by 2-3x on valuation. Pharma-adjacent chemical businesses are achieving the highest multiples in the sector. The question is not how much you produce, but how replaceable your product is.

Jeroen van den Berg

Sector Lead Consumer • 14 years • 90+ transactions

“In chemicals, the valuation gap between specialty and commodity is wider than in any other industrial sector. A specialty formulator serving pharma or EV supply chains can achieve 8x or more. A commodity producer in the same revenue range? We struggle to get past 5x.”

Sector at a Glance

  • Updated March 2, 2026
VALUATION RANGE

0.0x – 0.0x

↑ +0.2x vs 2024

EBITDA Multiple
Deals in 2025

0

Active Buyers

0+

Enter your figures → see your position instantly

Valuation Development

Chemicals valuations peaked in 2022 on pricing power, corrected sharply in 2023, and are selectively recovering. Specialty segments lead the rebound.

5-Year Multiple Range

2021 PEAK

0.0x avg

Post-COVID supply shortage windfall

2023 DIP

0.0x avg

Correction: input costs, destocking

2025 NOW

0.0x avg

Selective: specialty up, commodity flat

Subsegment Analysis

Specialty Chemicals

[XX] deals in 2025

Multiple Range

0x  – 0.0x

+0.5x
Buyer Mix
PE 40% • Strategic 50%
Key Valuation Driver
Application specificity and customer lock-in
Am I in this segment? →

Fine / Pharma Chemicals

[XX] deals in 2025

Multiple Range

0x  – 0x

+0.8x
Buyer Mix
PE 35% • Strategic 55%
Key Valuation Driver
Regulatory certifications and contract base
Am I in this segment? →

Commodity / Basic Chemicals

[XX] deals in 2025

Multiple Range

0.0x  – 0.0x

+0.0x
Buyer Mix
PE 15% • Strategic 70%
Key Valuation Driver
Scale, capacity utilization, and feedstock access
Am I in this segment? →

Chemical Distribution

[XX] deals in 2025

Multiple Range

0.0x  – 0x

+0.3x
Buyer Mix
PE 45% • Strategic 45%
Key Valuation Driver
Geographic coverage and supplier exclusivity
Am I in this segment? →

Buyer Landscape 2025

Overall Buyer Type Distribution

  • What drives premium valuations

Proprietary formulations with customer qualification

+0.0x to +0.0x

Regulatory certifications (GMP, REACH, ISO)

+0.0x to +0.0x

End-market diversification (pharma, EV, electronics)

+0.0x to +0.0x

Contracted/recurring revenue base above 50%

+0.0x to +0.0x

Sustainable chemistry / low-carbon processes

+0.0x to +0.0x

Which of these buyers match your firm?

BuyersChecker analyzes your profile against our active buyer database.

Recent Transactions

Formulation Premium

Specialty Chemicals

Specialty chemical formulator serving automotive and electronics OEMs with custom adhesive and coating solutions

REVENUE

€0.0M

EBITDA

€0.0M

MULTIPLE

0.0x

DURATION

0 months

Proprietary formulations
OEM qualification
65% contracted revenue

Key Insight

The customer lock-in from proprietary formulations was the decisive premium driver. Each product was qualified into the customer production process, making switching costs extremely high. Without this stickiness, the multiple would have been 2x lower.

Certification Premium

Fine Chemicals

Contract development and manufacturing organization for pharmaceutical intermediates with GMP certification and long-term supply agreements

REVENUE

€0.0M

EBITDA

€0.0M

MULTIPLE

0.0x

DURATION

0 months

GMP certified
80% contracted
Pharma supply chain

Key Insight

GMP certification and validated manufacturing processes created a significant barrier to entry. The PE buyer valued the 80% contracted revenue and pharmaceutical customer base as a platform for further CDMO acquisitions.

Platform Value

Distribution

Regional chemical distributor with exclusive supplier agreements, hazmat logistics capability, and Benelux-wide coverage

REVENUE

€0.0M

EBITDA

€0.0M

MULTIPLE

0.0x

DURATION

0 months

Hazmat capability
Exclusive suppliers
Benelux coverage

Key Insight

Distribution margins are thin but PE buyers valued the regional consolidation opportunity. Exclusive supplier agreements and hazmat capability created defensible competitive advantages that justified a premium over generic distribution.

Commodity Discount

Basic Chemicals

Mid-size producer of basic industrial chemicals with modern plant but high feedstock dependency and limited product differentiation

REVENUE

€0.0M

EBITDA

€0.0M

MULTIPLE

0.0x

DURATION

0 months

Scale-dependent
Modern plant asset
Limited differentiation

Key Insight

Without product differentiation or customer lock-in, the valuation was compressed to capacity and asset value. The process took longer due to limited buyer pool and cyclicality concerns. Commodity producers need to demonstrate margin resilience across cycles.

Recognize yourself in these cases? Compare your situation.

Market Trends 2025

Specialty vs commodity gap widening

Specialty chemicals with proprietary formulations and customer lock-in consistently achieve multiples 2-3x higher than commodity producers. The gap has widened as buyers prioritize defensible margins over scale.

Source: KBS Corporate Dec 2025, Capstone

~0x

valuation gap

Pharma-adjacent chemicals command premiums

Chemical companies serving pharmaceutical supply chains, including CDMOs and intermediate producers with GMP certification, are achieving the highest multiples in the sector. Regulatory barriers create natural moats.

Source: Capstone Jul 2025, Clairfield H1 2025

0.0x

avg pharma chem deal

ESG and sustainable chemistry driving deals

Bio-based chemicals, recycling-integrated production, and low-carbon manufacturing processes are emerging as valuation premiums. European regulation (REACH, CSRD) is accelerating this shift.

Source: CEFIC, PwC M&A Trends 2025

0.0%

of buyers check ESG

Volume down, quality up

Chemical M&A transaction volume declined significantly in 2025, but quality of assets trading improved. Large-cap divestitures (Shell, portfolio pruning) are creating mid-market opportunities for well-positioned buyers.

Source: Capstone Chemicals Update Jul 2025

–0.0%

YoY deal volume decline

What This Means for You

Interactive tools that give you immediate insights—or full reports in your personal portal.

30 sec

Marktlink Multiple

Your estimated valuation

Direct: Indicative multiple

Portal: Detailed range + comparable deals
+ factors breakdown

Start tool

30 sec

BuyersChecker

How many buyers match you

Direct: Number of matches

Portal: Buyer profiles + alerts when
new buyers match

Start tool

30 sec

Benchmark Tool

Your performance vs sector

Direct: Position indication

Portal: Full benchmark report
+ quarterly updates

Start tool

30 sec

Buyer Appeal Scan

Which buyers want you

Direct: Top buyer type

Portal: All buyer types ranked + appeal factors
+ matching profiles

Start tool

1 min

Timing Scan

Market timing analysis

Direct: Timing score

Portal: Detailed timing report
+ market alerts

Start tool

2 min

Sale Readiness Test

How prepared are you

Direct: Readiness score

Portal: Full assessment
+ personalized action plan

Start tool

Industry Report 2025

Everything on this page, plus: 12 additional deal cases, detailed subsegment analysis, and 2026 outlook.

Follow This Sector

Receive updates when valuations change, new buyers emerge, or relevant deals close.

  • Valuation changes
  • Deal announcements
  • New buyer profiles
  • Quarterly updates